CALC (CalciMedica, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by CALC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-24 | ALAFI CAPITAL CO LLC | 10%+ Owner | A | — | — |
| 2026-08-21 | A. Rachel Leheny | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2026-08-21 | Eric W Roberts | CHIEF BUSINESS OFFICER | A | — | — |
| 2026-08-21 | Allan Shaw | Director | A | — | — |
| 2026-08-21 | Evgeny Zaytsev | Director | A | — | — |
| 2026-08-21 | Alan Glicklich | Director | A | — | — |
| 2026-08-21 | Sudarshan Hebbar | Chief Medical Officer | A | — | — |
| 2026-08-21 | Frederic Guerard | Director | A | — | — |
| 2026-08-21 | ROBERT N WILSON | Director | A | — | — |
| 2026-07-07 | Evgeny Zaytsev | Director | A | — | — |
| 2026-06-29 | Sudarshan Hebbar | Chief Medical Officer | A | — | — |
| 2026-06-29 | ROBERT N WILSON | Director | A | — | — |
| 2026-06-29 | A. Rachel Leheny | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2026-06-29 | Fred A Middleton | Director | Buy | — | — |
| 2026-06-29 | Eric W Roberts | CHIEF BUSINESS OFFICER | A | — | — |
| 2026-04-07 | Stephen Bardin | Chief Financial Officer | A | — | — |
| 2026-04-07 | Sudarshan Hebbar | Chief Medical Officer | A | — | — |
| 2026-04-07 | Michael J. Dunn | President and COO | A | — | — |
| 2026-04-07 | Eric W Roberts | CHIEF BUSINESS OFFICER | A | — | — |
| 2026-04-07 | A. Rachel Leheny | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2026-04-07 | Kenneth A. Stauderman | Chief Scientific Officer | A | — | — |
| 2025-10-14 | Alan Glicklich | Director | A | — | — |
| 2025-09-22 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | — | — |
| 2025-09-17 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | — | — |
| 2025-09-15 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | — | — |
| 2025-09-11 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | — | — |
| 2025-09-02 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | — | — |
| 2025-08-25 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | — | — |
| 2025-08-21 | Sudarshan Hebbar | Chief Medical Officer | Buy | — | — |
| 2025-08-21 | Eric W Roberts | CHIEF BUSINESS OFFICER | MIXED | — | — |
| 2025-08-19 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | — | — |
| 2025-08-18 | Sudarshan Hebbar | Chief Medical Officer | Buy | — | — |
| 2025-07-29 | Kenneth A. Stauderman | Chief Scientific Officer | MIXED | — | — |
| 2025-07-23 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | — | — |
| 2025-07-22 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | — | — |
| 2025-07-21 | A. Rachel Leheny | CHIEF EXECUTIVE OFFICER | Buy | — | — |
| 2025-07-18 | ROBERT N WILSON | Director | Buy | — | — |
| 2025-07-18 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | — | — |
| 2025-07-16 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | — | — |
| 2025-07-15 | A. Rachel Leheny | CHIEF EXECUTIVE OFFICER | Buy | — | — |
| 2025-07-10 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | — | — |
| 2025-07-02 | Kenneth A. Stauderman | Chief Scientific Officer | Buy | — | — |
| 2025-06-27 | Eric W Roberts | CHIEF BUSINESS OFFICER | Buy | — | — |
| 2025-06-26 | A. Rachel Leheny | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2025-06-26 | Eric W Roberts | CHIEF BUSINESS OFFICER | A | — | — |
| 2025-06-26 | Michael J. Dunn | President and COO | A | — | — |
| 2025-06-26 | Sudarshan Hebbar | Chief Medical Officer | A | — | — |
| 2025-06-26 | FRED A MIDDLETON | Director | A | — | — |
| 2025-06-26 | Kenneth A. Stauderman | Chief Scientific Officer | A | — | — |
| 2025-06-26 | Allan Shaw | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,022,469 | — |
| — | Director | 320,930 | — |
| — | Director | 196,652 | — |
| — | 10%+ Owner | 195,407 | — |
| — | 10%+ Owner | 142,455 | — |
| — | CHIEF BUSINESS OFFICER | 136,509 | — |
| — | 10%+ Owner | 84,644 | — |
| — | CHIEF EXECUTIVE OFFICER | 76,777 | — |
| — | Chief Medical Officer | 37,205 | — |
| — | Chief Executive Officer | 22,222 | — |
| — | Chief Financial Officer | 9,601 | — |
| — | Chief Financial Officer | 8,600 | — |
| — | Chief Medical Officer | 5,796 | — |
| — | Chief Scientific Officer | 2,589 | — |
| — | Director | 707 | — |
| — | Director | 286 | — |
| — | Director | 286 | — |
| — | Director | 286 | — |
| — | Director | 286 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CALC quote page; the site-wide leaderboard is on the insider transactions hub.